Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
Status:
RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.
Phase:
PHASE1
Details
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborators:
Shengqi Medical Technology (Guangzhou) Co., Ltd. Viyun (Xiamen) Biomedical Research Institute Co., Ltd.